Citations (76)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Sooyoung Shin & Hyunah Kim. (2016) The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study. Therapeutics and Clinical Risk Management 12, pages 435-444.
Read now
Read now
André J Scheen. (2013)
Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation. Expert Opinion on Drug Metabolism & Toxicology 9:3, pages 363-377.
Read now
Read now
Robert J. Greene, Hua Tu, John P. Gibbs & J. Greg Slatter. (2011) Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222. Xenobiotica 41:11, pages 945-957.
Read now
Read now
Baptist Gallwitz. (2011) Sitagliptin and metformin combination therapy for the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 6:4, pages 543-556.
Read now
Read now
Baptist Gallwitz. (2010) New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin. Diabetes, Metabolic Syndrome and Obesity 3, pages 117-124.
Read now
Read now
André J Scheen. (2010) Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opinion on Drug Metabolism & Toxicology 6:10, pages 1265-1276.
Read now
Read now
Thomas D Aicher, Steven A Boyd, Maralee McVean & Anthony Celeste. (2010) Novel therapeutics and targets for the treatment of diabetes. Expert Review of Clinical Pharmacology 3:2, pages 209-229.
Read now
Read now
James R. LaSalle. (2010) Reaching HbA1c Goals with Saxagliptin in Combination with Other Oral Antidiabetic Drugs. Postgraduate Medicine 122:1, pages 144-152.
Read now
Read now
Sunmin PARK, Sang Mee HONG, Il Sung AHN, Yang Jin KIM & Jung Bok LEE. (2009) Huang-Lian-Jie-Du-Tang Supplemented with Schisandra chinensis Baill. and Polygonatum odoratum Druce Improved Glucose Tolerance by Potentiating Insulinotropic Actions in Islets in 90% Pancreatectomized Diabetic Rats. Bioscience, Biotechnology, and Biochemistry 73:11, pages 2384-2392.
Read now
Read now
Kjetil Retterstøl. (2009) Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue. Expert Opinion on Investigational Drugs 18:9, pages 1405-1411.
Read now
Read now
Articles from other publishers (66)
Muhammad Imran Ali & Muhammad Moazzam Naseer. (2023)
Recent biological applications of heterocyclic hybrids containing
s
-triazine scaffold
. RSC Advances 13:43, pages 30462-30490.
Crossref
Crossref
Justin T. CallPedro CortésDana M. Harris. (2022) A practical review of diabetes mellitus type 2 treatment in primary care. Romanian Journal of Internal Medicine 60:1, pages 14-23.
Crossref
Crossref
Yingze Liu, Xiangjun Meng, Yuyao Zhang, Linge Zhang, Yuqin Shan, Jingkai Gu & Dong Sun. (2021) High‐throughput bioanalysis of sitagliptin in plasma using direct analysis in real time mass spectrometry and its application in the pharmacokinetic study thereof. Journal of Separation Science 45:2, pages 631-637.
Crossref
Crossref
Donald J. AbrahamAnn E. Weber & Nancy A. Thornberry. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
48
.
Virendra Nath, Manish Ramchandani, Neeraj Kumar, Rohini Agrawal & Vipin Kumar. (2021) Computational identification of potential dipeptidyl peptidase (DPP)-IV inhibitors: Structure based virtual screening, molecular dynamics simulation and knowledge based SAR studies. Journal of Molecular Structure 1224, pages 129006.
Crossref
Crossref
Melissa A. Luse, Emily M. Heiston, Steven K. Malin & Brant E. Isakson. (2020) Cellular and Functional Effects of Insulin Based Therapies and Exercise on Endothelium. Current Pharmaceutical Design 26:30, pages 3760-3767.
Crossref
Crossref
Navneet Kumar Upadhyay, Charul Rathore, Sameer Sapra & Poonam Negi. (2018) NOVEL RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF SAXAGLIPTIN AND GLIMEPIRIDE. International Journal of Applied Pharmaceutics, pages 151-156.
Crossref
Crossref
Byung-Jin Jung, Hwan-Sic Yoo, Sooyoung Shin, Young-Joon Park & Sang-Min Jeon. (2018) Dysregulation of NRF2 in Cancer: from Molecular Mechanisms to Therapeutic Opportunities. Biomolecules & Therapeutics 26:1, pages 57-68.
Crossref
Crossref
Yoojin Noh, Dae Ryong Kang, Dae Jung Kim, Kwang Jae Lee, Sukhyang Lee & Sooyoung Shin. (2017) Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies. Pharmacoepidemiology and Drug Safety 26:11, pages 1338-1346.
Crossref
Crossref
Scott M Brown, Cassandra E Smith, Alex I Meuth, Maloree Khan, Annayya R Aroor, Hannah M Cleeton, Gerald A Meininger, James R Sowers, Vincent G DeMarco, Bysani Chandrasekar, Ravi Nistala & Shawn B Bender. (2017) Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Ameliorates Angiotensin II–Induced Cardiac Diastolic Dysfunction in Male Mice. Endocrinology 158:10, pages 3592-3604.
Crossref
Crossref
Priyanka A. Shah, Jaivik V. Shah, Mallika Sanyal & Pranav S. Shrivastav. (2017) LC-MS/MS analysis of metformin, saxagliptin and 5-hydroxy saxagliptin in human plasma and its pharmacokinetic study with a fixed-dose formulation in healthy Indian subjects. Biomedical Chromatography 31:3, pages e3809.
Crossref
Crossref
Lea Duvnjak & Kristina Blaslov. (2016) Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome 8:1.
Crossref
Crossref
Priyanka A. Shah, Jaivik V. Shah, Mallika Sanyal & Pranav S. Shrivastav. (2016) LC–tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction. Journal of Pharmaceutical and Biomedical Analysis 131, pages 64-70.
Crossref
Crossref
Joseph R. Lizza, Savan V. Patel, Catherine F. Yang & Gustavo Moura-Letts. (2016) Direct Synthesis of Cyanopyrrolidinyl β-Amino Alcohols for the Development of Diabetes Therapeutics. European Journal of Organic Chemistry 2016:30, pages 5160-5168.
Crossref
Crossref
Leona Wagner, Florian Kaestner, Raik Wolf, Harald Stiller, Ulrich Heiser, Susanne Manhart, Torsten Hoffmann, Jens-Ulrich Rahfeld, Hans-Ulrich Demuth, Matthias Rothermundt & Stephan von Hörsten. (2016) Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation. Neuropeptides 57, pages 21-34.
Crossref
Crossref
Bernd Kuhn, Wolfgang Guba, Jérôme Hert, David Banner, Caterina Bissantz, Simona Ceccarelli, Wolfgang Haap, Matthias Körner, Andreas Kuglstatter, Christian Lerner, Patrizio Mattei, Werner Neidhart, Emmanuel Pinard, Markus G. Rudolph, Tanja Schulz-Gasch, Thomas Woltering & Martin Stahl. (2016) A Real-World Perspective on Molecular Design. Journal of Medicinal Chemistry 59:9, pages 4087-4102.
Crossref
Crossref
Toshio Morikawa, Kiyofumi Ninomiya, Junji Akaki, Namiko Kakihara, Hiroyuki Kuramoto, Yurie Matsumoto, Takao Hayakawa, Osamu Muraoka, Li-Bo Wang, Li-Jun Wu, Seikou Nakamura, Masayuki Yoshikawa & Hisashi Matsuda. (2015) Dipeptidyl peptidase-IV inhibitory activity of dimeric dihydrochalcone glycosides from flowers of Helichrysum arenarium. Journal of Natural Medicines 69:4, pages 494-506.
Crossref
Crossref
Rieko Takano, Masao Yoshida, Masahiro Inoue, Takeshi Honda, Ryutaro Nakashima, Koji Matsumoto, Tatsuya Yano, Tsuneaki Ogata, Nobuaki Watanabe, Masakazu Hirouchi, Takako Kimura & Narihiro Toda. (2015) Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558. Bioorganic & Medicinal Chemistry 23:17, pages 5546-5565.
Crossref
Crossref
Xin-gang Yao, Xin Xu, Gai-hong Wang, Min Lei, Ling-ling Quan, Yan-hua Cheng, Ping Wan, Jin-pei Zhou, Jing Chen, Li-hong Hu & Xu Shen. (2015) BBT improves glucose homeostasis by ameliorating β-cell dysfunction in type 2 diabetic mice. Journal of Endocrinology 224:3, pages 327-341.
Crossref
Crossref
Yohei Ikuma, Hitoshi Hochigai, Hidenori Kimura, Noriko Nunami, Tomonori Kobayashi, Katsuya Uchiyama, Takashi Umezome, Yasumitsu Sakurai, Naoyuki Sawada, Jun Tadano, Eiji Sugaru, Michiko Ono, Yuko Hirose & Hiroyuki Nakahira. (2015) Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: Use of a carboxylate prodrug to improve bioavailability. Bioorganic & Medicinal Chemistry 23:4, pages 779-790.
Crossref
Crossref
Apoorva G. UgarkarPremlata K. AmbreEvans C. CoutinhoSantosh NandanRaghuvir R.S. Pissurlenkar. (2014) Extracting structural requirements for activity of GPR119 agonists: a hologram quantitative structure activity relationship (HQSAR) study. Canadian Journal of Chemistry 92:7, pages 670-676.
Crossref
Crossref
Elisabeth Defossa & Michael Wagner. (2014) Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus. Bioorganic & Medicinal Chemistry Letters 24:14, pages 2991-3000.
Crossref
Crossref
Pratik Devasthale, Ying Wang, Wei Wang, John Fevig, JianXin Feng, Aiying Wang, Tom Harrity, Don Egan, Nathan Morgan, Michael Cap, Aberra Fura, Herbert E. Klei, Kevin Kish, Carolyn Weigelt, Lucy Sun, Paul Levesque, Frederic Moulin, Yi-Xin Li, Robert Zahler, Mark S. Kirby & Lawrence G. Hamann. (2013)
Optimization of Activity, Selectivity, and Liability Profiles in 5-Oxopyrrolopyridine DPP4 Inhibitors Leading to Clinical Candidate (
Sa
)-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5
H
-pyrrolo[3,4-
b
]pyridin-6(7
H
)-yl)-
N
,
N
-dimethylacetamide (BMS-767778)
. Journal of Medicinal Chemistry 56:18, pages 7343-7357.
Crossref
Crossref
Yen-Michael S Hsu & Daniel C Link. (2012) Enhancing hematopoietic growth factor performance. Nature Medicine 18:12, pages 1740-1741.
Crossref
Crossref
John P. Gibbs, Jill Fredrickson, Todd Barbee, Itzela Correa, Brian Smith, Shao‐Lee Lin & Megan A. Gibbs. (2013) Quantitative Model of the Relationship Between Dipeptidyl Peptidase‐4 (DPP‐4) Inhibition and Response: Meta‐Analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results. The Journal of Clinical Pharmacology 52:10, pages 1494-1505.
Crossref
Crossref
Yohei Ikuma, Hitoshi Hochigai, Hidenori Kimura, Noriko Nunami, Tomonori Kobayashi, Katsuya Uchiyama, Yudai Furuta, Mutsuko Sakai, Masakuni Horiguchi, Yumi Masui, Kazuhiko Okazaki, Yasuhiro Sato & Hiroyuki Nakahira. (2012) Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors. Bioorganic & Medicinal Chemistry 20:19, pages 5864-5883.
Crossref
Crossref
Kenji Negoro, Yasuhiro Yonetoku, Hana Misawa-Mukai, Wataru Hamaguchi, Tatsuya Maruyama, Shigeru Yoshida, Makoto Takeuchi & Mitsuaki Ohta. (2012) Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists. Bioorganic & Medicinal Chemistry 20:17, pages 5235-5246.
Crossref
Crossref
Jin Sook Song, Kyeong-Ryoon Lee, Hyun Jin Kwon, Sang Dal Rhee, Min Sun Kim, Sung Hum Choi, Sung-Hack Lee, Im Sook Song, Jin Hee Ahn, Sung Hoon Ahn & Myung Ae Bae. (2012) Pharmacokinetics and Pharmacodynamics of KR-66223 a Novel DPP-4 Inhibitor. Drug Metabolism and Pharmacokinetics 27:2, pages 216-222.
Crossref
Crossref
Yohei Ikuma & Hiroyuki Nakahira. (2011) Preparation of 2-aminosubstituted 3H-imidazo[4,5-c]quinolin-4(5H)-ones by palladium-assisted internal biaryl coupling reaction. Tetrahedron 67:49, pages 9509-9517.
Crossref
Crossref
F. M. Keane, S. Chowdhury, T.-W. Yao, N. A. Nadvi, M. G. Gall, Y. Chen, B. Osborne, A. J. V. Ribeiro, W. B. Church, G. W. McCaughan, M. D. Gorrell & D. M. T. Yu. 2011. Proteinases as Drug Targets. Proteinases as Drug Targets
118
144
.
Raffaele Marfella & Giuseppe Paolisso. (2011) Reply to the ?Comments on the article ?Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations??, by Avogaro (Journal of Diabetes and Its Complications 25 [2011] 352?353). Journal of Diabetes and its Complications 25:6, pages 405-406.
Crossref
Crossref
Pleun C.M. van Poppel, Mihai G. Netea, Paul Smits & Cees J. Tack. (2011) Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes. Diabetes Care 34:9, pages 2072-2077.
Crossref
Crossref
James E. Signorovitch, Eric Q. Wu, Elyse Swallow, Evan Kantor, Liangyi Fan & Jean-Bernard Gruenberger. (2011) Comparative Efficacy of Vildagliptin and Sitagliptin in Japanese Patients with Type 2 Diabetes Mellitus. Clinical Drug Investigation 31:9, pages 665-674.
Crossref
Crossref
Bianca Ahrens. (2011) Antibodies in metabolic diseases. New Biotechnology 28:5, pages 530-537.
Crossref
Crossref
Deanna S. Kania, Jasmine D. Gonzalvo & Zachary A. Weber. (2011) Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus. Clinical Therapeutics 33:8, pages 1005-1022.
Crossref
Crossref
Hironobu Maezaki, Yoshihiro Banno, Yasufumi Miyamoto, Yuusuke Moritou, Tomoko Asakawa, Osamu Kataoka, Koji Takeuchi, Nobuhiro Suzuki, Koji Ikedo, Takuo Kosaka, Masako Sasaki, Shigetoshi Tsubotani, Akiyoshi Tani, Miyuki Funami, Yoshio Yamamoto, Michiko Tawada, Kathleen Aertgeerts, Jason Yano & Satoru Oi. (2011) Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554. Bioorganic & Medicinal Chemistry 19:15, pages 4482-4498.
Crossref
Crossref
B. Gallwitz. (2011) Gemeinsamkeiten und Unterschiede inkretinbasierter TherapienSimilarities and differences of incretin-based therapies. Der Diabetologe 7:5, pages 301-307.
Crossref
Crossref
Thi-Mai Anh Dao, Aur?lie Waget, Pascale Klopp, Matteo Serino, Christelle Vachoux, Laurent Pechere, Daniel J. Drucker, Serge Champion, Sylvain Barth?lemy, Yves Barra, R?my Burcelin & Eric S?r?e. (2011) Resveratrol Increases Glucose Induced GLP-1 Secretion in Mice: A Mechanism which Contributes to the Glycemic Control. PLoS ONE 6:6, pages e20700.
Crossref
Crossref
Heung Jae Kim, Woo Young Kwak, Jong Pil Min, Jae Young Lee, Tae Hyun Yoon, Ha Dong Kim, Chang Yell Shin, Mi Kyung Kim, Song Hyen Choi, Hae Sun Kim, Eun Kyoung Yang, Ye Hwang Cheong, Yu Na Chae, Kyung Jin Park, Ji Myun Jang, Soo Jung Choi, Moon Ho Son, Soon Hoe Kim, Moohi Yoo & Bong Jin Lee. (2011) Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry Letters 21:12, pages 3809-3812.
Crossref
Crossref
Antonio R Chacra, Gerry H Tan, Shoba Ravichandran, James List & Roland Chen. (2011) Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diabetes and Vascular Disease Research 8:2, pages 150-159.
Crossref
Crossref
Bo Ahrén. (2011) Are Sulfonylureas Less Desirable Than DPP-4 Inhibitors as Add-on to Metformin in the Treatment of Type 2 Diabetes?. Current Diabetes Reports 11:2, pages 83-90.
Crossref
Crossref
Yasufumi Miyamoto, Yoshihiro Banno, Tohru Yamashita, Tatsuhiko Fujimoto, Satoru Oi, Yusuke Moritoh, Tomoko Asakawa, Osamu Kataoka, Hiroaki Yashiro, Koji Takeuchi, Nobuhiro Suzuki, Koji Ikedo, Takuo Kosaka, Shigetoshi Tsubotani, Akiyoshi Tani, Masako Sasaki, Miyuki Funami, Michiko Amano, Yoshio Yamamoto, Kathleen Aertgeerts, Jason Yano & Hironobu Maezaki. (2011) Discovery of a 3-Pyridylacetic Acid Derivative (TAK-100) as a Potent, Selective and Orally Active Dipeptidyl Peptidase IV (DPP-4) Inhibitor. Journal of Medicinal Chemistry 54:3, pages 831-850.
Crossref
Crossref
Carolyn Robertson. (2011) Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview. Diabetes Spectrum 24:1, pages 26-35.
Crossref
Crossref
Eric P. Davidson, Lawrence J. Coppey, Brian Dake & Mark A. Yorek. (2011) Treatment of Streptozotocin-Induced Diabetic Rats with Alogliptin: Effect on Vascular and Neural Complications. Experimental Diabetes Research 2011, pages 1-7.
Crossref
Crossref
S. Kasichayanula, X. Liu, W. C. Shyu, W. Zhang, M. Pfister, S. C. Griffen, T. Li, F. P. LaCreta & D. W. Boulton. (2011) Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes, Obesity and Metabolism 13:1, pages 47-54.
Crossref
Crossref
Yasufumi Miyamoto, Yoshihiro Banno, Tohru Yamashita, Tatsuhiko Fujimoto, Satoru Oi, Yusuke Moritoh, Tomoko Asakawa, Osamu Kataoka, Koji Takeuchi, Nobuhiro Suzuki, Koji Ikedo, Takuo Kosaka, Shigetoshi Tsubotani, Akiyoshi Tani, Miyuki Funami, Michiko Amano, Yoshio Yamamoto, Kathleen Aertgeerts, Jason Yano & Hironobu Maezaki. (2011) Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125. Bioorganic & Medicinal Chemistry 19:1, pages 172-185.
Crossref
Crossref
Baptist Gallwitz. 2011. Diabetes - Perspectives in Drug Therapy. Diabetes - Perspectives in Drug Therapy
53
74
.
T. Forst, B. Uhlig-Laske, A. Ring, U. Graefe-Mody, C. Friedrich, K. Herbach, H.-J. Woerle & K. A. Dugi. (2010) Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabetic Medicine 27:12, pages 1409-1419.
Crossref
Crossref
Jayne Hodgkiss. (2010) Incretin-based therapies for type 2 diabetes: a nurse’s perspective. British Journal of Nursing 19:21, pages 1337-1344.
Crossref
Crossref
Shigeru Yoshida, Takahide Ohishi, Tetsuo Matsui, Hirotsugu Tanaka, Hiroyuki Oshima, Yasuhiro Yonetoku & Masayuki Shibasaki. (2010) Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice. Biochemical and Biophysical Research Communications 402:2, pages 280-285.
Crossref
Crossref
W. E. Schmidt. (2010) Early clinical studies with liraglutide. International Journal of Clinical Practice 64, pages 12-20.
Crossref
Crossref
Shigeru Yoshida, Takahide Ohishi, Tetsuo Matsui & Masayuki Shibasaki. (2010) Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Biochemical and Biophysical Research Communications 400:3, pages 437-441.
Crossref
Crossref
Baptist Gallwitz. (2010) The evolving place of incretin-based therapies in type 2 diabetes. Pediatric Nephrology 25:7, pages 1207-1217.
Crossref
Crossref
Markus Boehringer, Holger Fischer, Michael Hennig, Daniel Hunziker, Joerg Huwyler, Bernd Kuhn, Bernd M. Loeffler, Thomas Luebbers, Patrizio Mattei, Robert Narquizian, Elena Sebokova, Urs Sprecher & Hans Peter Wessel. (2010) Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors. Bioorganic & Medicinal Chemistry Letters 20:3, pages 1106-1108.
Crossref
Crossref
Patrizio Mattei, Markus Boehringer, Patrick Di Giorgio, Holger Fischer, Michael Hennig, Joerg Huwyler, Buelent Ko?er, Bernd Kuhn, Bernd M. Loeffler, Alexander MacDonald, Robert Narquizian, Etienne Rauber, Elena Sebokova & Urs Sprecher. (2010) Discovery of carmegliptin: A potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry Letters 20:3, pages 1109-1113.
Crossref
Crossref
Donald J. AbrahamAnn E. Weber & Nancy A. Thornberry. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
39
76
.
B. Gallwitz & H.‐U. Häring. (2009) Future perspectives for insulinotropic agents in the treatment of type 2 diabetes–DPP‐4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism 12:1, pages 1-11.
Crossref
Crossref
Unmesh Shah & Timothy J. Kowalski. 2010. Incretins and Insulin Secretion. Incretins and Insulin Secretion
415
448
.
Samuel Grossman. (2012) Differentiating Incretin Therapies Based on Structure Activity, and Metabolism: Focus on Liraglutide. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29:12P2.
Crossref
Crossref
Olga V. Danilova, Albert K. Tai, Deanna A. Mele, Martin Beinborn, Andrew B. Leiter, Andrew S. Greenberg, James W. PerfieldIIII, Jason DeFuria, Praful S. Singru, Ronald M. Lechan & Brigitte T. Huber. (2009) Neurogenin 3-Specific Dipeptidyl Peptidase-2 Deficiency Causes Impaired Glucose Tolerance, Insulin Resistance, and Visceral Obesity. Endocrinology 150:12, pages 5240-5248.
Crossref
Crossref
Carolyn Robertson. (2009) New developments in incretin-based therapies: The current state of the field. Journal of the American Academy of Nurse Practitioners 21, pages 631-641.
Crossref
Crossref
M. Serino, E. Luche, C. Chabo, J. Amar & R. Burcelin. (2009) Intestinal microflora and metabolic diseases. Diabetes & Metabolism 35:4, pages 262-272.
Crossref
Crossref
Scott D. Edmondson, Anthony Mastracchio, Jason M. Cox, George J. Eiermann, Huaibing He, Kathryn A. Lyons, Reshma A. Patel, Sangita B. Patel, Aleksandr Petrov, Giovanna Scapin, Joseph K. Wu, Shiyao Xu, Bing Zhu, Nancy A. Thornberry, Ranabir Sinha Roy & Ann E. Weber. (2009) Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors. Bioorganic & Medicinal Chemistry Letters 19:15, pages 4097-4101.
Crossref
Crossref
Nancy A. Thornberry & Baptist Gallwitz. (2009) Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Practice & Research Clinical Endocrinology & Metabolism 23:4, pages 479-486.
Crossref
Crossref
Thomas E Hughes. (2009) Emerging therapies for metabolic diseases—the focus is on diabetes and obesity. Current Opinion in Chemical Biology 13:3, pages 332-337.
Crossref
Crossref
Bo Ahrén. (2009) Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nature Reviews Drug Discovery 8:5, pages 369-385.
Crossref
Crossref